Recombinant ADAMTS13 shows no significant difference in acute TTP events versus standard therapy or placebo in phase 2 and 3 trials
New drug raises enzyme levels but shows no clear benefit over standard care for TTP
This systematic review and meta-analysis evaluates recombinant ADAMTS13 in patients with congenital or acquired thrombotic thrombocytopenic …
A new treatment boosts enzyme activity in blood disorders but offers no clear advantage over standard therapy based on current evidence.
HMA-venetoclax yields 50% overall response rate in relapsed/refractory AML meta-analysis
Combination therapy shows response in relapsed leukemia
This systematic review and meta-analysis of 2289 adults with relapsed/refractory acute myeloid leukemia found that hypomethylating agents pl…
For adults with relapsed leukemia, combining two drugs led to a 50% response rate, offering a potential new option for a tough situation.
Systematic review reveals high prevalence of sickle cell disease across infants and youth in sub-Saharan Africa
Sickle cell disease affects nearly 2 percent of kids under 15 in sub-Saharan Africa
A comprehensive meta-analysis of 40 studies from 22 nations highlights the burden of sickle cell disease in sub-Saharan Africa. Prevalence r…
New analysis shows sickle cell disease is more common than thought in infants and children across sub-Saharan Africa, highlighting a critica…
Non-pharmacological interventions in adult ICU patients did not improve health-related quality of life in this network meta-analysis
Non-drug ICU care shows promise but needs more proof to help patients
This network meta-analysis evaluated non-pharmacological interventions for adult ICU patients. The analysis included 2,654 patients and comp…
Non-drug treatments in the ICU may improve quality of life, but results were not statistically significant and need more research.
NINJ1 targeting shows potential for multiple sclerosis and other neurological conditions but faces significant knowledge gaps
NINJ1 targeting shows promise for multiple sclerosis and other brain injuries
This narrative review examines NINJ1 targeting as a therapeutic strategy for multiple sclerosis, ischemic stroke, traumatic brain injury, sp…
A review suggests NINJ1 targeting could help treat multiple sclerosis, stroke, and other brain injuries, though more research is needed.
Xatmep receives FDA approval for pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis
FDA approves Xatmep for pediatric leukemia and arthritis treatment options
The FDA has approved Xatmep for pediatric patients with acute lymphoblastic leukemia or active polyarticular juvenile idiopathic arthritis. …
The FDA has approved Xatmep to treat specific forms of childhood leukemia and arthritis, offering new options for young patients.
Reduced-intensity ATRA plus arsenic with GO or low-dose anthracycline improves event-free survival in high-risk APL
New analysis shows reduced-intensity treatment works well for high-risk leukemia patients compared to standard intensive chemotherapy
This systematic review and meta-analysis of 1,323 patients with high-risk acute promyelocytic leukemia found that reduced-intensity inductio…
A large review of over 1,300 patients found that a gentler treatment plan worked just as well as harsher chemotherapy. This approach may hel…
Clinical and laboratory abnormalities linked to higher mortality in malaria patients with acute kidney injury
Severe lab changes in malaria patients with kidney injury strongly predict death
This systematic review and meta-analysis evaluated the relationship between various clinical and laboratory abnormalities and mortality in m…
Severe lab changes like low blood pressure or breathing trouble in malaria patients with kidney injury greatly increase the risk of dying.
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
FDA Approves Venclexta (venetoclax) for CLL/SLL and AML
FDA approves new drug Venclexta for certain blood cancers
FDA approved Venclexta (venetoclax) for adult patients with CLL or SLL, and in combination with azacitidine, decitabine, or low-dose cytarab…
The FDA approved Venclexta (venetoclax) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is also a…
FDA Approves Argatroban for Thrombosis in Heparin-Induced Thrombocytopenia
FDA approves Argatroban to treat blood clots in patients with HIT
The FDA approved argatroban for prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT) and as …
The FDA approved Argatroban to prevent or treat blood clots in adults with heparin-induced thrombocytopenia (HIT), a condition where heparin…
TEG-ROTEM guided transfusion may lower death and bleeding in cardiac surgery
New blood management tools may lower death risk during heart surgery, but proof is weak
A systematic review finds TEG-ROTEM guided transfusion may reduce mortality and bleeding in elective cardiac surgery, but evidence certainty…
A review suggests new blood tests could reduce death and bleeding during heart surgery, yet the evidence remains very uncertain and mostly c…